Search Bar & Filters
Found 18 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the safety and effectiveness of T3011, a herpesvirus injection, combined with PD-1PD-L1 inhibitors in adults with advanced solid tumors. This clinical trial aims to evaluate how well this combination treatment works and how well patients tolerate it, with the study sponsored by Shanghai Pharmaceuticals Holding Co., Ltd. It is a Phase IbIIa trial conducted at multiple centers. Participants will receive T3011 injected directly into tumors every two weeks, along with PD-1PD-L1 inhibitors given by intravenous infusion at a dose of 3 mgkg also every two weeks. Different dose levels of T3011 high, middle, and low are being tested to assess safety and initial effectiveness. The study does not include a placebo group and is open-label, meaning both researchers and participants know the treatments being given. During the study, participants will be closely monitored for side effects and treatment responses over about two years. Researchers will measure outcomes such as the rate of treatment-related adverse events, objective response rate, disease control rate, duration of remission, progression-free survival, and overall survival. Participants will undergo regular assessments including physical exams, laboratory tests, and imaging to track their progress and safety throughout the trial.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of Pimicotinib ABSK021 combined with chemotherapy, with or without the addition of Toripalimab, in patients with advanced pancreatic cancer. This phase II, open-label study aims to understand how well this combination works and how safe it is for people with non-resectable local advanced or metastatic pancreatic cancer. The study is sponsored by Abbisko Therapeutics Co, Ltd and focuses on patients who have not received prior systemic treatment for pancreatic cancer. Participants receive Pimicotinib orally once daily along with chemotherapy drugs Gemcitabine and nab-Paclitaxel given by intravenous infusion on days 1 and 8 of each 21-day cycle. In one group, Toripalimab is also given intravenously on day 1 of each cycle. Treatment lasts about 24 weeks, covering approximately eight cycles. The study includes two cohorts in both parts A and B to compare the combination with and without Toripalimab. During the study, participants undergo assessments to monitor safety events from the day they consent until 90 days after completing eight cycles, as well as evaluations of tumor response. Researchers also track the duration of response, progression-free survival, overall survival, and drug levels in the blood during the treatment period. Participants complete all study procedures as outlined by the researchers, who guide them through the process to evaluate the treatments effects over time.
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are evaluating the efficacy and safety of a new drug called STN1013800 ophthalmic solution for treating acquired blepharoptosis in Chinese patients. This condition involves drooping of the upper eyelid, and currently, there are no approved medicines for this in China. This is a Phase III randomized, double-masked, placebo-controlled study designed to compare STN1013800 with a placebo solution. Participants will receive either 0.1% STN1013800 ophthalmic solution or a placebo once daily for 42 days, based on prior clinical trial results. The study includes a screening period lasting 3 to 7 days to confirm eligibility. The interventions involve applying the assigned eye drops daily, with the study treatment and placebo groups monitored in parallel. During the study, participants will undergo multiple assessments including margin reflex distance-1 MRD-1 measurements and Leicester Peripheral Field Test LPFT scores at several time points Day 1 Hour 6, Day 14 Hour 2, and Day 42. Researchers will track changes from baseline in eyelid position and visual function to evaluate treatment effects. Safety and adherence will also be monitored throughout the 42-day treatment period.
Actively Recruiting
Researchers are evaluating whether metformin, compared with a placebo, can improve heart function in patients after they receive a Left Ventricular Assist Device LVAD. This study focuses on patients who have insulin resistance but controlled blood sugar levels and aims to find out if metformin can help heart metabolism and function beyond its usual use for diabetes. The trial is a randomized, double-blind, placebo-controlled study involving 108 patients across five centers in China. Participants are randomly assigned to one of two groups one receiving metformin and the other receiving a placebo. Metformin is given orally following a dose-escalation schedule over 10 weeks to reach a target dose, followed by a maintenance period up to 12 months. The placebo group follows the same schedule with identical-looking tablets. Dose adjustments may be made based on tolerance and kidney function during the treatment period. Throughout the study, participants undergo regular assessments including heart function tests such as echocardiography and blood biomarker measurements at multiple time points up to 24 months after LVAD implantation. Researchers will monitor clinical events like hospitalization, mortality, and device-related complications, as well as quality of life and exercise capacity. Safety is closely watched through adverse event reporting and laboratory tests. The primary outcome is the rate of participants meeting strict criteria for heart function improvement at 12 months post-implantation.
Actively Recruiting
This research aims to evaluate the safety and effectiveness of combining selinexor with azacitidine and venetoclax in adults newly diagnosed with acute myeloid leukemia AML who have not received prior treatment. The study is a prospective, single-arm, multi-center clinical trial focusing on patients who are either ineligible for or refuse intensive chemotherapy. It is designed to gather data on how well this combination works and its safety profile in this patient group. Participants will receive selinexor orally at 60 mg on days 3, 10, and 17 azacitidine intravenously at 75 mgm2 on days 1-3, 8-9, and 15-16 and venetoclax orally starting at 100 mg on day 1, increasing to 200 mg on day 2, and 400 mg on days 3-14 within each 28-day treatment cycle. Those who achieve complete remission may undergo a transplant at any time, while others will continue treatment until the disease progresses or unacceptable side effects occur. During the study, participants will be closely monitored for treatment response and safety through assessments including remission rates up to about two years. Secondary measures include overall survival, response rates, minimal residual disease negativity, and recurrence-free survival over approximately four years. The total participation time varies based on individual outcomes, with ongoing evaluations to track effectiveness and side effects throughout the study period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of Autologous Tumor Infiltrating Lymphocytes GT101 injection compared with Gemcitabine in women with recurrent or metastatic cervical cancer. This Phase II study is conducted at multiple centers and involves random assignment to one of two treatment groups. It aims to provide important information about these treatments for patients who have already received prior systemic therapy for this cancer. Participants will receive either GT101 injection, a biological treatment derived from the patients own tumor cells, or Gemcitabine injection, a chemotherapy drug. The study is open-label, meaning both the participants and researchers know which treatment is given. Treatments are administered according to the study protocol and monitored for effects over time. During the study, women will undergo regular assessments to evaluate disease progression, treatment response, and safety. This includes imaging scans measured by RECIST 1.1 criteria and monitoring for side effects using standardized criteria. The main outcome measured is progression-free survival over three years, along with duration of response and treatment-related adverse events. Participants will be followed for up to three years to track these outcomes.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of two different treatment regimens to eradicate Helicobacter pylori infection. This trial compares a dual therapy using linralase glutarate capsules combined with amoxicillin against a quadruple therapy that includes bismuth. The main goal is to see if the dual therapy is not less effective than the quadruple therapy, while also monitoring patient adherence and side effects. This is a phase 4, randomized, open-label study aimed at first-line treatment of this infection. Participants receive either the dual-drug regimen of linralase glutarate capsules 50 mg twice daily plus amoxicillin 1 g three times daily or the quadruple therapy consisting of esomeprazole 20 mg twice daily, clarithromycin 0.5 g twice daily, amoxicillin 1 g twice daily, and colloidal bismuth subcitrate 200 mg twice daily. Both treatment courses last for 14 days. The study groups are assigned randomly and monitored during and after treatment to assess outcomes. During the study, participants undergo testing to determine the Helicobacter pylori eradication rate 28 days after treatment ends. Researchers also track adverse events during the 14 days of treatment and for 28 days following treatment completion. Participants adherence to the medication regimens is evaluated throughout. The trial includes adults aged 18 to 70 years who meet specific diagnostic and health criteria. The total duration from treatment to outcome measurement spans about 6 weeks, including follow-up assessments.
Actively Recruiting
This research aims to evaluate whether MM09, a sublingual immunotherapy, can help patients aged 12 to 65 with moderate-to-severe allergic rhinitis or rhinoconjunctivitis caused by house dust mites, with or without mild to moderate asthma. The trial is a phase III, randomized, double-blind, placebo-controlled study designed to assess if MM09 reduces symptoms and the need for rescue medications, while also monitoring safety. Participants will receive either the active MM09 sublingual spray or a placebo solution without the active ingredient. The treatment is given daily over 12 months. The study carefully compares the effects of MM09 against placebo to understand its impact on allergic rhinitisrhinoconjunctivitis and asthma symptoms. During the study, participants will record symptoms and medication use via a smartphone app. Researchers will measure combined symptom and medication scores, as well as separate scores for rhinitis, rhinoconjunctivitis, and asthma symptoms and medication intake during the last four weeks of treatment. Safety and any medical problems from inhaling MM09 will be closely monitored throughout the trial, which lasts up to 12 months.
Actively Recruiting
Acute myocardial infarction AMI, especially ST-segment elevation myocardial infarction STEMI, remains a leading cause of death worldwide despite advances in reperfusion treatments. Mortality rates remain significant even when primary percutaneous coronary intervention pPCI is timely administered, and many survivors develop heart failure. This trial explores the role of leukotriene C4 LTC4 in myocardial ischemia-reperfusion injury IRI and investigates montelukast, a leukotriene receptor antagonist, as a potential therapy to reduce heart damage and improve outcomes in STEMI patients undergoing pPCI. Participants will be randomly assigned to receive either montelukast at a dose of 10 mg daily or a placebo for three months following enrollment. The study is triple-masked, meaning that participants, care providers, and researchers do not know which treatment is given. The treatment period aims to assess the effects of montelukast on heart protection after the acute myocardial event. Throughout the study, participants will be monitored for changes in left ventricular remodeling over 24 weeks from enrollment to the end of treatment. The trial includes assessments of heart function and structure, with cardiac magnetic resonance imaging used to evaluate outcomes. Safety and tolerance of the treatment will also be observed, and patient progress will be followed up during the 6-month study period to measure cardiac function and remodeling improvements.
1-10 of 18
1